RTTNews | Sep 1, 2020 07:33AM EDT

07:33 Tuesday, September 1, 2020 (RTTNews.com) - Plus Therapeutics, Inc. (PSTV) announced the FDA has granted the company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes for the treatment of patients with recurrent glioblastoma. Rhenium NanoLiposomes is being evaluated in the NIH/NCI-supported, multi-center ReSPECT Phase 1 dose-finding clinical trial. The Data Safety and Monitoring Board has approved the company to proceed to Cohort 6 in ReSPECT Trial.

Rhenium NanoLiposomes is designed to safely deliver a very high dose of radiation - up to 25 times greater concentration than currently used external beam radiation therapy - directly into the brain tumor for maximum effect.

Read the original article on RTTNews ( https://www.rttnews.com/3125296/plus-therapeutics-receives-fda-orphan-drug-designation-for-rhenium-nanoliposomes.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved